Growth differentiation factor 15 associations with clinical features of chronic heart failure with midrange ejection fraction and preserved ejection fraction depending on the history of myocardial infarction

Aim    To analyze associations between levels of the inflammatory marker, growth differentiation factor 15 (GDF-15), and echocardiographic indexes in CHF patients with mid-range and preserved left ventricular ejection fraction (LV EF) depending on the history of myocardial infarction (MI).
Material and methods    This study included 34 CHF patients with preserved and mid-range LV EF after MI (group 1, n=19) and without a history of MI (group 2, n=15). Serum concentration of GDF-15 was measured with enzyme immunoassay (BioVendor, Czech Republic). Statistical analysis was performed with STATISTICA 10.0.
Results    Patients of the study groups were age-matched [62 (58;67) and 64 (60;70) years, p=0.2] but differed in the gender; group 1 consisted of men only (100 %) whereas in group 2, the proportion of men was 53.3 % (p=0.001). Median concentration of GDF-15 was 2385 (2274; 2632.5) and 1997 (1534;2691) pg/ml in groups 1 and 2, respectively (p=0.09). Patients without MI showed a moderate negative correlation between LV EF and GDF-15 concentration (r= – 0.51, p=0.050) and a pronounced correlation between GDF-15 and LV stroke volume (r= –0.722, p=0.002). For patients after MI, a correlation between the level of GDF-15 and the degree of systolic dysfunction was not found (р>0.05).
Conclusion    Blood concentration of the inflammatory marker, GDF-15, correlates with LV EF and stroke volume in CHF patients with preserved or mid-range LV EF and without a history of MI while no such correlations were observed for patients with a history of MI.

1. Ponikowski PA, Voors AD, Anker S, Bueno H, Cleland JGF, Coats A et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Russian Journal of Cardiology. 2017;22(1):7–81. DOI: 10.15829/1560-4071-2017-1-7-81

2. Beggs SAS, McDonagh TA, Gardner RS. Chronic heart failure: epidemiology, investigation and management. Medicine. 2018;46(10):594– 600. DOI: 10.1016/j.mpmed.2018.07.006

3. Longjian Liu, Howard J. Eisen. Epidemiology of Heart Failure and Scope of the Problem. Cardiology Clinics. 2014;32(1):1–8. DOI: 10.1016/j.ccl.2013.09.009

4. Papadimitriou L, Hamo CE, Butler J. Heart failure guidelines: What’s new? Trends in Cardiovascular Medicine. 2017;27(5):316–23. DOI: 10.1016/j.tcm.2017.01.003

5. Drapkina O.M., Palatrina L.O. New emphases on the study of the pathogenesis of chronic heart failure with preserved ejection fraction: focus on inflammatory markers. Rational Pharmacotherapy in Cardiology. 2014;10(3):317–21.

6. Kuster N, Huet F, Dupuy A, Akodad M, Battistella P, Agullo A et al. Multimarker approach including CRP, sST2 and GDF‐15 for prognostic stratification in stable heart failure. ESC Heart Failure. 2020;7(5):2230–9. DOI: 10.1002/ehf2.12680

7. Jirak P, Pistulli R, Lichtenauer M, Wernly B, Paar V, Motloch LJ et al. Expression of the Novel Cardiac Biomarkers sST2, GDF-15, suPAR, and H-FABP in HFpEF Patients Compared to ICM, DCM, and Controls. Journal of Clinical Medicine. 2020;9(4):1130. DOI: 10.3390/jcm9041130

8. Arkoumani M, Papadopoulou-Marketou N, Nicolaides NC, KanakaGantenbein C, Tentolouris N, Papassotiriou I. The clinical impact of growth differentiation factor-15 in heart disease: A 2019 update. Critical Reviews in Clinical Laboratory Sciences. 2020;57(2):114–25. DOI: 10.1080/10408363.2019.1678565

9. Savic-Radojevic A, Pljesa-Ercegovac M, Matic M, Simic D, Radovanovic S, Simic T. Novel Biomarkers of Heart Failure. Advances in Clinical Chemistry. 2017; 79:93–152. DOI: 10.1016/bs.acc.2016.09.002

10. Kempf T, von Haehling S, Peter T, Allhoff T, Cicoira M, Doehner W et al. Prognostic Utility of Growth Differentiation Factor-15 in Patients with Chronic Heart Failure. Journal of the American College of Cardiology. 2007;50(11):1054–60. DOI: 10.1016/j.jacc.2007.04.091

11. Mendez Fernandez AB, Ferrero‐Gregori A, Garcia‐Osuna A, Mirabet‐Perez S, Pirla‐Buxo MJ, Cinca‐Cuscullola J et al. Growth differentiation factor 15 as mortality predictor in heart failure patients with non‐reduced ejection fraction. ESC Heart Failure. 2020;7(5):2223–9. DOI: 10.1002/ehf2.12621

12. Stahrenberg R, Edelmann F, Mende M, Kockskämper A, Düngen H-D, Lüers C et al. The novel biomarker growth differentiation factor 15 in heart failure with normal ejection fraction. European Journal of Heart Failure. 2010;12(12):1309–16. DOI: 10.1093/eurjhf/hfq151

13. Izumiya Y, Hanatani S, Kimura Y, Takashio S, Yamamoto E, Kusaka H et al. Growth Differentiation Factor-15 Is a Useful Prognostic Marker in Patients with Heart Failure With Preserved Ejection Fraction. Canadian Journal of Cardiology. 2014;30(3):338–44. DOI: 10.1016/j.cjca.2013.12.010

14. Xu X, Nie Y, Wang F, Bai Y, Lv Z, Zhang Y et al. Growth Differentiation Factor (GDF)-15 Blocks Norepinephrine-induced Myocardial Hypertrophy via a Novel Pathway Involving Inhibition of Epidermal Growth Factor Receptor Transactivation. Journal of Biological Chemistry. 2014;289(14):10084–94. DOI: 10.1074/jbc.M113.516278

15. Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8–158. DOI: 10.18087/cardio.2475

16. Mitchell C, Rahko PS, Blauwet LA, Canaday B, Finstuen JA, Foster MC et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. Journal of the American Society of Echocardiography. 2019;32(1):1–64. DOI: 10.1016/j.echo.2018.06.004

17. Wollert KC, Kempf T, Peter T, Olofsson S, James S, Johnston N et al. Prognostic Value of Growth-Differentiation Factor-15 in Patients With Non–ST-Elevation Acute Coronary Syndrome. Circulation. 2007;115(8):962–71. DOI: 10.1161/CIRCULATIONAHA.106.650846

18. Khan SQ, Ng K, Dhillon O, Kelly D, Quinn P, Squire IB et al. Growth differentiation factor-15 as a prognostic marker in patients with acute myocardial infarction. European Heart Journal. 2009;30(9):1057–65. DOI: 10.1093/eurheartj/ehn600

19. Syvolap V.D., Zemlyanoy Ya.V. The relationship of the growth factor of differentiation of the 15, N-terminal fragment of the brain natriuretic peptide with heart remodeling in patients with heart failure with preserved ejection fraction after myocardial infarction with arterial hypertension. Scientific Bulletin of the Belgorod State University. Series: Medicine. Pharmacy. 2014;18(189):68–73.

20. Baessler A, Strack C, Rousseva E, Wagner F, Bruxmeier J, Schmiedel M et al. Growth-differentiation factor-15 improves reclassification for the diagnosis of heart failure with normal ejection fraction in morbid obesity. European Journal of Heart Failure. 2012;14(11):1240–8. DOI: 10.1093/eurjhf/hfs116

21. He J, Zhang Y, Xu T, Zhao Q, Wang D, Chen C-S et al. Effects of Immediate Blood Pressure Reduction on Death and Major Disability in Patients with Acute Ischemic Stroke: The CATIS Randomized Clinical Trial. JAMA. 2014;311(5):479–89. DOI: 10.1001/jama.2013.282543

22. Dalos D, Spinka G, Schneider M, Wernly B, Paar V, Hoppe U et al. New Cardiovascular Biomarkers in Ischemic Heart Disease-GDF-15, A Probable Predictor for Ejection Fraction. Journal of Clinical Medicine. 2019;8(7):924. DOI: 10.3390/jcm8070924

23. Horckmans M, Ring L, Duchene J, Santovito D, Schloss MJ, Drechsler M et al. Neutrophils orchestrate post-myocardial infarction healing by polarizing macrophages towards a reparative phenotype. European Heart Journal. 2016;38(3):187–97. DOI: 10.1093/eurheartj/ehw002

24. Mollenhauer M, Friedrichs K, Lange M, Gesenberg J, Remane L, Kerkenpaß C et al. Myeloperoxidase Mediates Postischemic Arrhythmogenic Ventricular Remodeling. Circulation Research. 2017;121(1):56–70. DOI: 10.1161/CIRCRESAHA.117.310870